Protocol Ledger

NCT05710692 · Phase II/III · RECRUITING

Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease

Interventional Phase II/III clinical trial protocol NCT05710692 sponsored by Chiesi Farmaceutici S.p.A in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-08-01 Enrollment: 16 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05710692
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)16 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05710692
Protocol FieldVerified Registry Value
NCT IdentifierNCT05710692
Consolidated Lead SponsorChiesi Farmaceutici S.p.A
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment16 participants (ESTIMATED)
Registered Start Date2023-08-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05710692
Hospital Research SiteLocationSite Profile
Tohoku University HospitalSendai, JapanOpen Hospital Dossier ->
Keio University HospitalShinjuku-ku, JapanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI